R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

First International Summit on Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Apr

Today In Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC

Romiplostim for Chemotherapy-Induced Thrombocytopenia

AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms

Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma

Is Standard of Care Optimal for the Individual Patient?